Medtech stories we missed this week: June 22, 2018

From Accuray’s India approval to Masimo and PositiveID launching a Bluetooth-enabled thermometer, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. India approves Accuray’s Radixact X9 radiation therapy device Accuray announced in a June 21 press release that it has received an Atomic Energy Regulatory Board Type Approval in India

No-shows at radiology can cost a hospital $1 million a year, study says

People who fail to show up for radiology appointments cost hospitals about $1 million per year on average, according to a new study. That’s as much as the cost of a new 3T MR scanner. Most of the no-shows at academic medical centers were for mammography appointments, according to the study, published in Current Problems

This robotic system can automatically adjust ultrasound equipment

Neural Analytics today announced that it has won FDA clearance for a robotic system that can automatically adjust the company’s ultrasound equipment to monitor blood flow through the brain from outside the body. NeuralBot was designed to work with the company’s previously approved Lucid M1 transcranial Doppler ultrasound system, a portable all-in-one ultrasound system designed

Medtech stories we missed this week: April 6, 2018

From CHF Solutions’s distribution deal to Guided Therapeutics’s licensing agreement, here are seven medtech stories we missed this week but throught were still worth mentioning. 1. CHF inks Spanish distribution deal CHF Solutions announced in an April 5 press release that it has signed a distribution agreement with Dimedix Surgical. The distribution agreement will allow

Ultrasound imaging and blood tests could catch liver cancer in early stages

Researchers at the University of Texas Southwestern have recently discovered that combining ultrasound images with blood tests that test for high alpha fetoprotein (AFP) levels can improve detection of early-stage liver cancer by 40%. There are about 42,220 new liver cancer diagnoses and about 30,200 will die from it per year. It affects more men

This remote-controlled immunotherapy system targets and kills cancer cells

University of California researchers have developed a remote-controlled therapy system that identifies and kills cancer cells using ultrasound. The ultrasound-based system is able to non-invasively and remotely control the genetic process in immune T cells to identify and kill cancer cells. According to the researchers, the ability to non-invasively and remotely manipulate cells at a

Medtech stories we missed this week: Dec. 22, 2017

From Hepa Wash’s new collaboration to Stimwave’s FDA clearance, here are five medtech stories we missed this week but thought were still worth mentioning. 1. Hepa Wash collaborates with GALS program Hepa Wash announced in a Dec. 7 press release that it has collaborated with the German Accelerator Life Sciences (GALS) program to expand its

Alpha Source acquires BC Technical

Alpha Source announced that it has acquired BC Technical. The financial details of the deal were not immediately disclosed. The acquisition helps Alpha Source (Milwaukee, Wis.) double the size of its full service, imaging services and equipment repair solutions in the U.S. The company also says that the deal will expand its ultrasound and bone

A $10 microchip helps create 3D ultrasound images: Here’s how

Researchers have used the same accelerometer technology that comes in a smartphone to give $50,000 ultrasound machines 3D imaging capabilities using a $10 microchip. A team of doctors and engineers at Duke University and Stanford University have used a fingernail-sized microchip that is mounted on a traditional ultrasound probe to relay 2D images of what

Insightec wins most innovative medical technology of 2017

Insightec’s Exablate Neuro has won the Galien Foundation’s award for most innovative medical technology of 2017 at the 11th Annual Prix Galien USA Awards. The award ceremony took place on Oct. 26 at the American History Museum of Natural History in New York City. The Exablate Neuro is an ultrasound device that is FDA-approved to treat

Medtech stories we missed this week: Oct. 20, 2017

From InspireMD’s distribution deal to RenalGuard touting a new study, here are seven medtech stories we missed this week but thought were still worth a mention. 1. InspireMD inks Chile distribution deal InspireMD announced in an Oct. 12 press release that it has signed a distribution deal with CorpMedical Chile to distribute the MGuard Prime

Theraclion makes strides with echotherapy in Germany, Hong Kong

Theraclion (Malakoff, France) today announced wins when it comes to use of its echotherapy treatment in Germany and Hong Kong. The Heilfürsorge Bundespolizei (medical insurance of the federal German police force) now covers echotherapy for both breast fibroadenomas and thyroid nodules. “It is a strong mark of recognition for our technology that the German federal police

Medtech stories we missed this week: August 4, 2017

From MDCorp inking a European distribution deal to Align Technology’s North Carolina expansion, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. MDCorp inks distribution deal with Smart Endoscope Systems MDCorp announced in a July 31 press release that it has signed a distribution agreement with Smart Endoscope

Researchers create ‘ultrasound drill’ to attack thrombosis

North Carolina researchers have developed a new surgical tool that uses low-frequency intravascular ultrasound to break down blood clots that could cause deep vein thrombosis. The ultrasound “drill”, called that because it can be aimed directly ahead, could allow physicians to better target clots and reduce treatment time, according to researchers from North Carolina State

Endra Life Sciences IPO to raise $8.4 million

Endra Life Sciences’s IPO offering, which closes tomorrow, is expected to raise $8.4 million as the company seeks to commercialize its Thermo Acoustic Enhanced Ultrasound (TAEUS) in Europe. Endra announced May 9 that the IPO would involve 1.68 million units – each including one share of common stock and a warrant to purchase an additional share of